Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.
Magda Opsomer, MD, Director, Clinical Leader, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, Belgium, explains why darunavir may be more beneficial than other HIV medications.
Interview Transcript (slightly modified for readability)
“Darunavir is a boosted protease inhibitor and what is special about it is that it has a very high genetic barrier to the development of resistance. [This] is very important when it comes to treating patients, because as we know, resistance makes it more difficult to treat patients at the end.”
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
2 Commerce Drive
Cranbury, NJ 08512